Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
Certainly in the United States, in the year 2000, most estrogen
receptor positive woman got five years of tamoxifen. So, for the
majority of those woman, if the woman is postmenopausal, I’m
going to give her an aromatase inhibitor, if the woman is premenopausal
I’m going to give her something like Zoladex or Lupron. For
the woman who either has a visceral crisis or who is steroid receptor
negative, I’m going to start the patient with some form of
chemotherapy, and again that chemotherapy will be highly dependent
upon what the patient got in an adjuvant setting. If the patient
received, as many of my patients have, an anthracycline in the adjuvant
setting and has relapsed relatively recently after the chemotherapy,
I’m likely to initiate the patient with a single agent taxane,
off of the protocol. The major change that has occurred in the last
two or three years, I think, it has come about as a result of Herceptin.
I think we have compelling evidence now that if a patient is HER2-positive,
that patient probably should be receiving Herceptin as part of the
initial therapy for the patient’s metastatic breast cancer.
Relevant
Links:
Anastrozole
is superior to tamoxifen as first-line therapy for advanced breast
cancer in postmenopausal women: Results of a North American multicenter
randomized trial.
Nabholtz, J. M.; Buzdar, A.; Pollak, M.; Harwin, W.; Burton, G.;
Mangalik, A.; Steinberg, M.; Webster, A., and von Euler, M. Journal
of Clinical Oncology. 18(22):3758-3767, 2000 Nov 15.
Biological
rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody
therapy [Review]. Pegram, M. and Slamon, D Seminars in Oncology. 27(5 Suppl 9):13-19,
2000 Oct. In
process
The
use of HER2 testing in the management of breast cancer [Review]. Ravdin, P. Seminars in Oncology. 27(5 Suppl 9):33-42, 2000 Oct.
In process
Low-dose
oral fluorouracil with eniluracil as first-line chemotherapy against
advanced breast cancer: A phase II study. Smith,
I. E.; Johnston, S. R. D.; O'Brien, M. E. R.; Hickish, T. F.; de
Boer, R. H.; Norton, A.; Cirkel, D. T., and Barton, C. M.. Journal
of Clinical Oncology. 18(12):2378-2384, 2000 Jun.
Comparison
of chemotherapy with chemohormonal therapy as first-line therapy-for
metastatic, hormone-sensitive breast cancer: An Eastern Cooperative
Oncology Group study. Sledge,
G. W.; Hu, P.; Falkson, G.; Tormey, D., and Abeloff, M.. Journal
of Clinical Oncology. 18(2):262-266, 2000 Jan.
Assessment
of the need for palliative care as perceived by individual cancer
patients and their families - A review of instruments for improving
patient participation in palliative care [Review]. Osse,
B. H. P.; Vernooij-Dassen MJFJ; de Vree, B. P. W.; Schade, E.,
and Grol RPTM. Cancer. 88(4):900-911, 2000 Feb 15.
Anastrozole
is superior to tamoxifen as first-line therapy for advanced breast
cancer in postmenopausal women: Results of a North American multicenter
randomized trial. Nabholtz,
J. M.; Buzdar, A.; Pollak, M.; Harwin, W.; Burton, G.; Mangalik,
A.; Steinberg, M.; Webster, A., and von Euler, M. Journal of Clinical
Oncology. 18(22):3758-3767, 2000 Nov 15.
The
role of tumour markers in improving the accuracy of conventional
chest X-ray and liver echography in the post-operative detection
of thoracic and liver metastases from breast cancer. Nicolini,
A.; Carpi, A.; Ferrari, P.; Anselmi, L.; Spinelli, C.; Conte, M.,
and Miccoli, P. (Reprint available from: Nicolini A Univ Pisa, Dept
Internal Med Pisa Italy).. British Journal of Cancer. 83(11):1412-1417,
2000 Dec. In process
Minimal
solid tumor involvement of regional and distant sites - When is
a metastasis not a metastasis?
Page,
D. L.; Anderson, T. J., and Carter, B. A. (Reprint available from:
Page DL
Vanderbilt Univ, Med Ctr, Dept Pathol C3311 Med Ctr N,1161 21st
Ave S Nashville, TN 37232 USA). Cancer. 86(12):2589-2592, 1999 Dec
15. No abstract
Radiation
therapy in the management of brain metastases from breast cancer.
Breast Cancer Research & Treatment. Fokstuen, T.; Wilking, N.; Rutqvist, L. E.; Wolke, J.; Liedberg,
A.; Signomklao, T., and Fernberg, J. O. (Reprint available from:
Fokstuen T Karolinska Hosp, Radiumhemmet, Dept Oncol S-17176 Stockholm
Sweden).. 62(3):211-216, 2000 Aug. In progress
Stereotactic
radiosurgery for brain metastases from breast cancer. Firlik, K. S.; Kondziolka, D.; Flickinger, J. C., and Lunsford,
L. D. Annals of Surgical Oncology. 7(5):333-338, 2000 Jun. In
progress
Combined
endocrine therapy for breast cancer - New life for an old idea? Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St,Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute 92(11):859-860, 2000 Jun 7. No
abstract
Biological
rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody
therapy [Review]. Pegram, M. and Slamon, D Seminars in Oncology.
27(5 Suppl 9):13-19, 2000 Oct.
In
process Current and planned clinical trials with trastuzumab (Herceptin)
[Review]. Baselga, J. Seminars in Oncology. 27(5 Suppl 9):27-32, 2000
Oct. In process
Clinical
trials of single-agent trastuzumab (Herceptin) [Review]. Seminars in Oncology. 27(5 Suppl 9):20-26, 2000 Oct. In proces
